A Viagra-like medication could turn around heart failure

-
New research in sheep shows that a drug that doctors usually prescribe for the treatment of erectile dysfunction can also treat heart failure.
In people with heart failure, the heart muscle becomes unable to pump out blood efficiently, meaning that some organs may not receive the amount of oxygen that they need to function properly.
The Centers for Disease Control and Prevention (CDC) note that 5.7 million adults in the United States have heart failure and that approximately half of the people with this condition die within about 5 years of receiving their diagnosis.
Moreover, research that Cardiac Failure Review published in 2017 argued that there is a "global pandemic" of heart failure, with this condition affecting an estimated 26 million people worldwide.
Such numbers suggest that finding new ways to treat heart failure is a priority for specialists who study this condition.
Recently, Prof. Andrew Trafford led a team of researchers from the University of Manchester in the United Kingdom who found that a drug that doctors typically use to treat erectile dysfunction could also treat systolic heart failure, in which the heart's left ventricle loses the ability to contract as normal.
The findings of the new study, which the researchers conducted in sheep, appeared today in the journal Scientific Reports.

Comments

Post a Comment

Popular posts from this blog

The Truth About Dealing With Heart Failure

-
A guide to reducing risks and living well even if you develop the condition Congestive heart failure is a serious illness. But it does not, as is sometimes thought, mean the heart stops ­altogether. It signifies that the muscle is damaged and can no longer pump enough blood to meet the body’s needs. This condition, which ­affects 1 in 5 adults—usually in the later years—can shorten life. But with proper treatment, people are living longer and better with heart failure. “We have more medications at our disposal today to improve quality of life for people with a weakened heart,” says Guy L. Mintz, M.D., director of cardiovascular health and lipidology at Sandra Atlas Bass Heart Hospital in Manhasset, N.Y. Here’s what to do. Coronary artery disease and heart attacks are major causes of heart failure, says cardiologist Tamara Horwich, M.D., medical director of UCLA’s cardiac rehabilitation program in Los Angeles. Managing your risk for problems—such as high blood pressure, h
Read more

Breaking Down Barriers in the Fight Against Congenital Heart Disease

-
Academic research has long been characterized by silos and protective instincts. A new crop of fresh-thinking physician scientists are turning that model on its head, and the results are saving little hearts. More than 1 in every 110 babies is born with some form of congenital heart disease. CHDs are the most common birth defect, in fact. Clinicians have made great strides in improving care for these children, and even individuals with severe diseases may now live well into adulthood. However, not all survive and many still experience significant complications.   “As a doctor in a pediatric cardiac ICU, we know there are things we want to do better,” says Michael Gaies, M.D., a cardiac intensivist and director of quality at the Congenital Heart Center at Michigan Medicine’s C.S. Mott Children’s Hospital. “We believe we can improve care for kids recovering from heart surgery if we can better control certain parts of the post-operative journey.” The problem? Data, or rather,
Read more

Cerebrovascular Disease: A Serious Complication After Allogeneic Hematopoietic Stem Cell Transplantation

-
A study published in the  International Journal of Hematology  found that the incidence of cerebrovascular disease (CVD) was approximately 10 times higher in patients after  allogeneic hematopoietic stem cell transplantation (HSCT) compared with the general Taiwanese population. Moreover, CVD was associated with the number of high-dose cytarabine courses given. The researchers retrospectively evaluated clinical data from adult patients who underwent HSCT at an Asian tertiary medical center between January 2003 and December 2015. The study aimed to estimate CVD incidence, identify associated host-related and transplant procedure-related risk factors, and measure clinical outcomes (overall survival [OS] and disease-free survival [DFS]). Data from 459 adult allogeneic HSCT recipients were assessed. Of this patient cohort, 4.4% (20/459) developed post-transplant CVD, 2.4% (11/459) had intracranial hemorrhage (ICH), and 2.2% (10/459) had cerebrovascular infarction. Median follow-up wa
Read more